| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Over the past 90 days, insiders at Teva Pharmaceutical Industries Limited (TEVA) have been net sellers, shedding 441,824 shares worth roughly $17.0M on balance.
TEVA sits in the Pharmaceuticals industry within the Health Care sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 2.12M | - | - | |
| CEO | 1.18M | - | - | |
| Dir | 448.0K | - | - | |
| Dir | 130.1K | - | - | |
| Dir | 127.7K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2020 | Drape Eric51 | Executive VP Global Operations | Sale+OE | 3,144 | $12.24 | $38,487.90 | -13.2% | |
| Feb 10, 2020 | Dethlefs Sven | EVP Global Marketing&Portfolio | Sale+OE | 5,669 | $12.27 | $69,558.63 | -23.9% | |
| Feb 10, 2020 | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sale+OE | 12,538 | $12.24 | $153,471.39 | -80.8% | |
| Feb 10, 2020 | Daniell Richard | Exec. VP, European Commercial | Sale+OE | 6,199 | $12.24 | $75,886.30 | -41.9% | |
| Feb 10, 2020 | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sale+OE | 5,544 | $12.27 | $68,024.88 | -14.3% | |
| Feb 10, 2020 | Nazzi Gianfranco | EVP, Growth Markets Commercial | Sale+OE | 4,155 | $12.24 | $50,864.26 | -18.4% | |
| Feb 10, 2020 | O'Grady Brendan P. | EVP, North America Commercial | Sale+OE | 4,799 | $12.27 | $58,883.73 | -26.3% | |
| Dec 31, 2019 | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sale+OE | 2,459 | $9.92 | $24,396.23 | -9.8% | |
| Dec 2, 2019 | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sale+OE | 4,310 | $10.49 | $45,214.49 | -17.3% | |
| Nov 5, 2019 | McClellan Michael James | EVP, Chief Financial Officer | Sale+OE | 242 | $8.83 | $2,137.85 | -1.5% |